Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXS Neuraxis, Inc.

Pre-Market Trading 03-31 05:09:35 EDT

2.10

-0.03

-1.42%

High2.16	Low2.07	Vol5.91K
Open2.07	D1 Closing2.13	Amplitude4.33%
Mkt Cap15.16M	Tradable Cap7.05M	Total Shares7.22M
T/O12.58K	T/O Rate0.18%	Tradable Shares3.36M
P/B7.35	ROE-2480.49%	EPS-1.22
52wk High3.78	52wk Low1.99	P/E-1.72
Dividend0.00	Div.Yield0.00	ROA-169.85%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NRXS","market":"US","secType":"STK","nameCN":"Neuraxis, Inc.","latestPrice":2.101,"timestamp":1743192000000,"preClose":2.1313,"halted":0,"volume":5913,"delay":0,"floatShares":3357478,"shares":7215864,"eps":-1.221694,"marketStatus":"Pre-Market Trading","change":-0.0303,"latestTime":"03-31 05:09:35 EDT","open":2.0678,"high":2.16,"low":2.0678,"amount":12581.3325,"amplitude":0.04326,"askPrice":3.34,"askSize":100,"bidPrice":0.9237,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.221694,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743427800000},"marketStatusCode":1,"adr":0,"listingDate":1691553600000,"exchange":"AMEX","adjPreClose":2.101,"volumeRatio":0.4990884153891156},"requestUrl":"/m/hq/s/NRXS/wiki","defaultTab":"wiki","newsList":[{"id":"2522708411","title":"NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708411","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708411?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 23:20","pubTimestamp":1742829600,"startTime":"0","endTime":"0","summary":"Shares of NeurAxis, Inc. NRXS have gained 0.9% since the company reported earnings for the quarter ended Dec. 31, 2024. This compares favorably to the S&P 500 Index, which declined 0.1% over the same time frame. Over the past month, NeurAxis stock has climbed 3.2%, while the S&P 500 saw a 5% decline.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.NeurAxis reported fourth-quarter 2024 revenues of $761 thousand, a 43% increase from $531 thousand a year earlier. This robust growth was primarily driven by a 45% increase in unit sales, reflecting stronger adoption of the company's IB-Stim therapy through both insurance-covered treatments and the company’s financial assistance program. For the full year, revenues rose 9.2% to $2.7 million from $2.5 million in 2023.CFO Tim Henrichs added that revenue growth in first-quarter 2025 has continued the momentum seen in the third and fourth quarters of 2024. He reiterated that NRXS is targeting c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-stock-gains-post-q4-152000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS","POST"],"gpt_icon":0},{"id":"2521264903","title":"NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2521264903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521264903?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 08:29","pubTimestamp":1742603350,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. (($NRXS)) has held its Q4 earnings call. Read on for the main highlights of the call. NeurAxis, Inc. recently held its fourth quarte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2521442264","title":"NeurAxis, Inc. Reports Strong Q4 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521442264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521442264?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 12:07","pubTimestamp":1742530068,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. ( ($NRXS) ) has released its Q4 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors. NeurAxis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-2024-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-2024-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2520455412","title":"Neuraxis reports Q4 revenue $761,000 vs. $531,000 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520455412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520455412?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:20","pubTimestamp":1742473219,"startTime":"0","endTime":"0","summary":"Brian Carrico, CEO commented, “Our strong performance in 4Q24 capped off a transformational year, as we significantly expanded insurance coverage f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-reports-q4-revenue-761000-vs-531000-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-reports-q4-revenue-761000-vs-531000-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS"],"gpt_icon":0},{"id":"2520545532","title":"Neuraxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2520545532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520545532?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:15","pubTimestamp":1742472900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA7RKVN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2520845598","title":"Press Release: NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2520845598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520845598?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:15","pubTimestamp":1742472900,"startTime":"0","endTime":"0","summary":"Conference call will be held today, Thursday, March 20 at 9:00 am ET. CARMEL, Ind., March 20, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.-- Revenues increased 43% to $761 thousand in 4Q24 compared to $531 thousand. Brian Carrico, Chief Executive Officer of NeurAxis, commented, \"Our strong performance in 4Q24 capped off a transformational year, as we significantly expanded insurance coverage for IB Stim, received a CPT Category I code for PENFS, nearly doubled our TAM for Pediatric FAB/IBS, and received 510 clearance for our RED device. These important accomplishments put us in an exceptional position to continue the outsized growth we have achieved in the last two quarters. Our growth prospects in the near and medium term are robust and extend across multiple prod","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2520345377","title":"Neuraxis Q4 EPS $(0.23) Up From $(0.85) YoY, Sales $761.16K Up From $531.46K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520345377","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520345377?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:07","pubTimestamp":1742472445,"startTime":"0","endTime":"0","summary":"Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.23) per share. This is a 72.94 percent increase over losses of $(0.85) per share from the same period last year.  The company reported $761.16 thousand in sales this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44414626/neuraxis-q4-eps-0-23-up-from-0-85-yoy-sales-761-16k-up-from-531-46k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neuraxis Q4 EPS $(0.23) Up From $(0.85) YoY, Sales $761.16K Up From $531.46K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2505458275","title":"NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States","url":"https://stock-news.laohu8.com/highlight/detail?id=2505458275","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505458275?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 22:00","pubTimestamp":1737468000,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Jan. 21, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation , with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome  in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy.Forward-Looking Statements Certain statements in this press release are forward","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-announces-medical-policy-coverage-140000944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014005.SGD","BK4082","MOH","SG9999014039.USD","BK4585","BK4154","BK4588","BK4532","NRXS","SG9999014021.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2503115300","title":"Neuraxis issues letter to shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2503115300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503115300?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 22:11","pubTimestamp":1736777512,"startTime":"0","endTime":"0","summary":"NeurAxis (NRXS) announced that CEO Brian Carrico has published a letter to shareholders. “We are thrilled to connect with you as we celebrate NeurA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-issues-letter-to-shareholders-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-issues-letter-to-shareholders-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2501720511","title":"Press Release: NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2501720511","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501720511?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 22:00","pubTimestamp":1736344800,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year. -- Revenues in 4Q24 increased approximately 50% versus 4Q23. CARMEL, Ind., Jan. 08, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced preliminary, unaudited revenues for the three and twelve months ended December 31, 2024. Revenues for 4Q24 were approximately $800 thousand, an increase of 50% compared to 4Q23. Revenues for FY2024 were approximately $2.7 million, an increase of 11% compared to FY2023. The Company had a cash balance of approximately $3.7 million as of 12/31/24.\"Importantly, we believe we are well positioned to achieve our near-term growth objectives with our strengthened balance sheet, including reaching cash flow breakeven. Our focus remains on strong growth combined with a prudent expense structure, which should resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2491583448","title":"Neuraxis files $25M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583448?lang=en_us&edition=full_marsco","pubTime":"2024-12-14 05:05","pubTimestamp":1734123951,"startTime":"0","endTime":"0","summary":"16:04 EST Neuraxis (NRXS) files $25M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-files-25m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-files-25m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2491583412","title":"Neuraxis files to sell 6.57M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583412","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583412?lang=en_us&edition=full_marsco","pubTime":"2024-12-14 05:05","pubTimestamp":1734123920,"startTime":"0","endTime":"0","summary":"16:04 EST Neuraxis (NRXS) files to sell 6.57M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-files-to-sell-6-57m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-files-to-sell-6-57m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2491758386","title":"Neuraxis Inc Files for Mixed Shelf of up to $25 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2491758386","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491758386?lang=en_us&edition=full_marsco","pubTime":"2024-12-14 05:02","pubTimestamp":1734123748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0T4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2491583844","title":"Neuraxis Inc: Selling Stockholders May Offer and Sell up to 6.6 Mln Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583844?lang=en_us&edition=full_marsco","pubTime":"2024-12-14 05:02","pubTimestamp":1734123748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0T4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2490152790","title":"Neuraxis Inc. Announces FDA 510(K) Clearance of Red for Testing and Evaluation of Patients With Chronic Constipation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490152790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490152790?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 22:00","pubTimestamp":1733839202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA5JDLFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2490015744","title":"Neuraxis Inc: Will Begin Process of Commercially Marketing Red and Expects Initial Revenues in 1Q25","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015744?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 22:00","pubTimestamp":1733839202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA5JDLFX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2490595016","title":"NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490595016","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490595016?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 22:00","pubTimestamp":1733839200,"startTime":"0","endTime":"0","summary":"RED has been designed to duplicate test performance of traditional balloon expulsion test  and manual sensation testing devices without needing electronics or software.NeurAxis Inc. will begin the process of commercially marketing RED and expects initial revenues in 1Q25 as there is a Category I CPT code assigned to the procedure and the procedure is covered by Medicare and most commercial insurance companies.CARMEL, Ind., Dec. 10, 2024  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the US Food and Drug Administration  granted a 510 clearance for RED , allowing NeurAxis to commercially market the device for testing and evaluation of patients with chronic constipation due to pelvic floor dyssynergia and who are unlikely to improve with increased laxative use.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mHav2rHq4M.GtBcEHYXg6Q--~B/aD05Mzt3PTMxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/112176ccffadb7603bfc377f6f44b7f5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-inc-announces-fda-510-140000376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2488983294","title":"BRIEF-Rosalind Advisors, Inc. Reports 9.9% Stake In Neuraxis Inc As Of November 12- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2488983294","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488983294?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 04:47","pubTimestamp":1733172470,"startTime":"0","endTime":"0","summary":"BRIEF-Rosalind Advisors, Inc. Reports 9.9% Stake In Neuraxis Inc As Of November 12- SEC FilingDec 2  - Neuraxis Inc NRXS.A:ROSALIND ADVISORS, INC. REPORTS 9.9% STAKE IN NEURAXIS INC AS OF NOVEMBER 12- SEC FILINGROSALIND ADVISORS: ON NOV 19, APPOINTED AHARON TO NEURAXIS BOARD, EFFECTIVE JAN 1, 2025 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N310U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2488599606","title":"Rosalind Advisors, Inc. Reports 9.9% Stake in Neuraxis Inc as of November 12- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2488599606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488599606?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 00:55","pubTimestamp":1733158522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N310U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2488066146","title":"Rosalind Advisors: on Nov 19, Appointed Aharon to Neuraxis Board, Effective Jan 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488066146","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488066146?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 00:55","pubTimestamp":1733158522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N310U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://neuraxis.com","stockEarnings":[{"period":"1week","weight":-0.0905},{"period":"1month","weight":-0.0182},{"period":"3month","weight":-0.1354},{"period":"6month","weight":-0.3372},{"period":"1year","weight":-0.3266},{"period":"ytd","weight":-0.106}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. NeurAxis, Inc. was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is based in Versailles, Indiana.","exchange":"AMEX","name":"Neuraxis, Inc.","nameEN":"Neuraxis, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neuraxis, Inc.,NRXS,Neuraxis, Inc.股票,Neuraxis, Inc.股票老虎,Neuraxis, Inc.股票老虎国际,Neuraxis, Inc.行情,Neuraxis, Inc.股票行情,Neuraxis, Inc.股价,Neuraxis, Inc.股市,Neuraxis, Inc.股票价格,Neuraxis, Inc.股票交易,Neuraxis, Inc.股票购买,Neuraxis, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuraxis, Inc.(NRXS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neuraxis, Inc.(NRXS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction